Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028966 | 1.00 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL3021201 | 0.92 | RIPK1 (0.32) | — | |
| SCHEMBL3021198 | 0.92 | RIPK1 (0.32) | — | |
| SCHEMBL3023934 | 0.90 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL3023930 | 0.90 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL3030562 | 0.89 | EZH2 (0.33) | — | |
| SCHEMBL3030566 | 0.89 | EZH2 (0.33) | — | |
| SCHEMBL3031799 | 0.86 | BRD4 (0.37) | MAPK1 | |
| SCHEMBL3031795 | 0.86 | BRD4 (0.37) | MAPK1 | |
| SCHEMBL3027314 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | claimed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | claimed |
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEM, LTD. (KR) | 2012-10-04 | — | — | US | disclosed |
| US-8222414-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2012-07-17 | — | — | US | disclosed |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | disclosed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | MAPK1 1650/4885 |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | MAPK1 1650/4885 |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | MAPK1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.